IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Rhea-AI Summary
IN8bio (Nasdaq: INAB) reported second quarter 2026 results and key clinical advances in its γδ T cell and γδ T cell engager portfolio. The INB-600 platform progressed with lead CD19-targeting engager INB-619 moving into IND-enabling studies after preclinical data showing complete B cell depletion, robust γδ T cell expansion and minimal CRS-associated cytokines, with initial in vivo data expected in the second half of 2026.
For newly diagnosed glioblastoma, updated DeltEx™ DRI data showed mPFS of 13.0 months vs 6.6 months for standard-of-care and mOS exceeding 19.5 months vs 13.2 months, with no DLTs, CRS or ICANS observed. Immune profiling showed an 18-fold increase in intratumoral CD8+ T cells and a 90% reduction in immunosuppressive granulocytes. As of June 30, 2026, cash was $18.0 million; Q2 R&D expenses were $2.5 million, G&A $2.4 million, and net loss $4.8 million ($0.25 per share), modestly improved from the prior-year quarter.
Positive
- Glioblastoma mPFS 13.0 vs 6.6 months with DeltEx DRI vs SOC
- Glioblastoma mOS exceeding 19.5+ vs 13.2 months with standard-of-care
- 24‑month survival 43% DeltEx repeat-dose vs 20% standard-of-care patients
- Favorable safety: no DLTs, CRS or ICANS in newly diagnosed GBM patients
- INB-619 advanced into IND-enabling studies after encouraging preclinical data
- Net loss Q2 2026 $4.8M vs $5.1M prior-year quarter; G&A down to $2.4M
Negative
- Cash and equivalents $17.96M at June 30, 2026, down from $27.09M at December 31, 2025
- Accumulated deficit widened to $150.97M as of June 30, 2026
- Q2 2026 net loss $4.78M; six‑month 2026 net loss $9.87M
- Total assets decreased to $21.75M at June 30, 2026 from $32.28M at year-end 2025
News Explained
The Q2 report leaves existing holders with a larger outstanding-share base and $18.0 million of cash at June 30, 2026.
IN8bio reported second-quarter 2026 financial results and business updates for the period ended
Its balance sheet listed
Cash was
Sources and calculations
- IN8bio Second Quarter 2026 Results Release (2026-08-06)
- IN8bio First-Quarter 2026 Fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $22,161,000 / ($4,947,000 / 90) = [object Object]
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | 1Q26 earnings | Positive | -1.3% | Clinical progress, INB-619 advancement, and $21.9M cash position |
| Mar 12 | FY25 earnings | Positive | -1.1% | GBM survival data, $27.1M cash, and private placement proceeds |
| Nov 06 | 3Q25 earnings | Positive | -6.6% | INB-619 preclinical data, INB-100 expansion, and quarterly financial results |
| Aug 07 | 2Q25 earnings | Positive | +7.4% | GBM progression-free survival and $13.2M cash position |
| May 07 | 1Q25 earnings | Positive | +2.1% | INB-100 survival data, $4.1M financing, and reduced net loss |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
IN8bio's earnings announcements produced divergent reactions, with negative moves in three of the five tag-specific events despite positive clinical and financial updates.
Key Terms
gamma delta (γδ) t cell engager medical
cytokine release syndrome medical
immune effector cell-associated neurotoxicity syndrome medical
spatial proteomics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026
- Presented updated data at ASCO 2026 demonstrating median overall survival (mOS) exceeding 19.5 months and still climbing, across all patients with newly diagnosed glioblastoma (GBM) treated with repeat-dosing of DeltEx™ Drug Resistant Immunotherapy (DRI)
- Published peer-reviewed clinical data from Phase 1 INB-200 trial in The Journal of Clinical Oncology (JCO) demonstrating DeltEx™ DRI more than doubled expected median progression-free survival (mPFS) in newly diagnosed GBM
- Reported new translational AI proteomic and immunogenomic analyses demonstrating DeltEx DRI preserves immune function and positively remodels the GBM tumor microenvironment, providing additional evidence supporting its therapeutic efficacy potential
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2026.
“The second quarter marked an important period of scientific and clinical validation for γδ T cell therapeutics and IN8bio. Our γδ TCE platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “In addition, peer-reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that γδ T cells are clinically active and can be delivered safely to potentially improve patient outcomes. We remain focused on disciplined execution, as we continue to seek a regulatory pathway for our glioblastoma program, with the ultimate goal of bringing much needed treatment to patients.”
Advancing Next-Generation γδ TCE Platform (INB-619)
- Continued advancement of proprietary INB-600 platform of novel γδ T cell engagers, designed to selectively eliminate targets such as CD19, potentially reducing toxicities including cytokine release syndrome (CRS) and infections, while expanding the therapeutic window compared with conventional CD3-targeting T cell engagers.
- Advancing INB-619, a CD19-targeting γδ T cell engager for oncology and autoimmune diseases, into IND-enabling studies following encouraging early preclinical data demonstrating complete B cell depletion, robust γδ T cell expansion, and minimal CRS-associated cytokine release, including IL-6 and TNF-α.
- Remain on track to report initial in vivo preclinical data in the second half of 2026.
Reported Clinical and Translational Advances for DeltEx™ DRI in Newly Diagnosed Glioblastoma
During the second quarter, IN8bio reported multiple clinical and scientific milestones supporting the clinical activity of γδ T cells and IN8bio’s DeltEx™ DRI platform:
- Published the first peer-reviewed clinical results of DeltEx DRI in newly diagnosed GBM in The Journal of Clinical Oncology. Among all patients treated, no dose-limiting toxicities (DLTs), CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.
- Presented updated clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating encouraging survival benefit in repeat-dose treated patients, with mPFS of 13.0 months versus 6.6 months for contemporaneously enrolled patients receiving only standard-of-care (SOC) and mOS exceeding 19.5+ months versus 13.2 months for SOC.
- Approximately
43% of repeat-dose patients remained alive at 24 months compared with20% of SOC patients.
- Approximately
- Presented new translational data at the International Society for Cell & Gene Therapy (ISCT) and International Society for Cell & Gene Therapy (ISCT) and American Society of Gene & Cell Therapy (ASGCT) Annual Meetings integrating artificial intelligence (AI), immunogenomics, histopathology, transcriptomics and spatial proteomics. Repeated DeltEx™ DRI dosing demonstrated preserved immune function during chemotherapy and positively remodeled the glioblastoma tumor microenvironment.
- Spatial proteomics analyses demonstrated an 18-fold increase in intratumoral CD8+ T cell density and a
90% reduction in immunosuppressive granulocytes, providing mechanistic support for the clinical activity observed with DeltEx™ DRI.
- Spatial proteomics analyses demonstrated an 18-fold increase in intratumoral CD8+ T cell density and a
- IN8bio Chief Scientific Officer Lawrence Lamb co-authored a review in Nature Communications highlighting advances in γδ T cell engineering, γδ T cell engagers, CAR γδ T cells and combination immunotherapy strategies, reinforcing IN8bio's scientific leadership in the rapidly expanding γδ T cell field.
- The publication highlights the potential of “off-the-shelf” γδ T cell therapies, driven by the cells’ lack of graft-versus-host disease (GvHD), and the growing clinical evidence supporting their application across hematologic malignancies and solid tumors, including GBM.
- The publication highlights the potential of “off-the-shelf” γδ T cell therapies, driven by the cells’ lack of graft-versus-host disease (GvHD), and the growing clinical evidence supporting their application across hematologic malignancies and solid tumors, including GBM.
Upcoming Anticipated Milestones
- Report initial preclinical animal data for INB-619 in the second half of 2026.
- Report on FDA discussions regarding the potential regulatory pathways for the DeltEx™ DRI GBM program.
- INB-100 program clinical update at a scientific meeting in late 2026.
- Provide additional clinical and translational updates from the DeltEx™ DRI GBM program.
Second Quarter 2026 Financial Highlights
- Cash position: As of June 30, 2026, the Company had cash of
$18.0 million , compared with$13.2 million , for the comparable prior year period. - Research and Development (R&D) expenses: R&D expenses were
$2.5 million for the three months ended June 30, 2026, compared with$2.5 million for the comparable prior year period. These amounts include non-cash items such as stock-based compensation (SBC) and depreciation. - General and administrative (G&A) expenses: G&A expenses were
$2.4 million for the three months ended June 30, 2026, compared with$2.7 million for the comparable prior year period. These amounts include non-cash items such as SBC and depreciation. - Net loss: The Company reported a net loss of
$4.8 million , or$0.25 per basic and diluted common share, for the three months ended June 30, 2026, compared with a net loss of$5.1 million , or$1.24 per basic and diluted common share, for the comparable prior year period.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio’s product candidates; the potential of IN8bio’s INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio’s ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways for the DeltEx™ DRI GBM program, expected presentations and data readouts from its preclinical studies and clinical trials including preclinical in vivo data for INB-619, patient dosing timelines and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
| IN8BIO, INC. BALANCE SHEETS (In thousands, except share and per share data) | |||||||
| June 30, | |||||||
| 2026 | December 31, | ||||||
| (unaudited) | 2025 | ||||||
| Assets | (Note 2) | ||||||
| Current assets | |||||||
| Cash | $ | 17,956 | $ | 27,092 | |||
| Prepaid expenses and other current assets | 540 | 788 | |||||
| Total Current Assets | 18,496 | 27,880 | |||||
| Non-current assets | |||||||
| Property and equipment, net | 1,600 | 1,858 | |||||
| Restricted cash | 176 | 220 | |||||
| Right-of-use assets - finance leases | 125 | 296 | |||||
| Right-of-use assets - operating leases | 1,246 | 1,882 | |||||
| Other non-current assets | 102 | 146 | |||||
| Total Non-Current Assets | 3,249 | 4,402 | |||||
| Total Assets | $ | 21,745 | $ | 32,282 | |||
| Liabilities and Stockholders' Equity | |||||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 444 | $ | 309 | |||
| Accrued expenses and other current liabilities | 761 | 1,633 | |||||
| Short-term finance lease liability | 126 | 295 | |||||
| Short-term operating lease liability | 923 | 924 | |||||
| Total Current Liabilities | 2,254 | 3,161 | |||||
| Long-term operating lease liability | 1,128 | 1,563 | |||||
| Total Non-Current Liabilities | 1,128 | 1,563 | |||||
| Total Liabilities | 3,382 | 4,724 | |||||
| Stockholders' Equity | |||||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 10 | 10 | |||||
| Additional paid-in capital | 169,320 | 168,644 | |||||
| Accumulated deficit | (150,967 | ) | (141,096 | ) | |||
| Total Stockholders' Equity | 18,363 | 27,558 | |||||
| Total Liabilities and Stockholders' Equity | $ | 21,745 | $ | 32,282 | |||
| IN8BIO, INC. STATEMENTS OF OPERATIONS (In thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 2,493 | $ | 2,487 | $ | 5,106 | $ | 5,459 | |||||||
| General and administrative | 2,442 | 2,714 | 5,095 | 5,402 | |||||||||||
| Total operating expenses | 4,935 | 5,201 | 10,201 | 10,861 | |||||||||||
| Interest income | 154 | 107 | 330 | 217 | |||||||||||
| Loss from operations | (4,781 | ) | (5,094 | ) | (9,871 | ) | (10,644 | ) | |||||||
| Net loss | $ | (4,781 | ) | $ | (5,094 | ) | $ | (9,871 | ) | $ | (10,644 | ) | |||
| Net loss per share – basic and diluted | $ | (0.25 | ) | $ | (1.24 | ) | $ | (0.51 | ) | $ | (3.65 | ) | |||
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 19,467,091 | 4,119,153 | 19,468,087 | 2,920,157 | |||||||||||
